Effect of chronic angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions

Journal of Invasive Cardiology

Volumn 23, Issue 2, 2011, Pages 72-75

  Aleti, Sumith ^a   Bansal, Darpan ^a   Agrawal, Mayank ^a   Uretsky, Barry F ^a   Sachdeva, Rajesh ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

angioplasty; angiotensin converting enzyme inhibitors; myocardial infarction; myonecrosis; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CREATINE KINASE ISOENZYME; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG EFFECT; DRUG ELUTING STENT; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PEROPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; SURGICAL MORTALITY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 79957597650     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bhatt D, Topol E. Does creatine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Circulation 2005;112:906-923.
2. Ghazzal Z, Ashfaq S, Morris DC, et al. Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J 2003;145:1006-1012. (Pubitemid 36688251)
3. Thygesen K, Alpert JS, White HD: Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-2195.
4. Blankenship JC, Tasissa G, O'Shea C et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001;38:653-658. (Pubitemid 32835731)
5. Steinhubl SR, Lauer MS, Mukherjee DP et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarction. J Am Coll Cardiol 1998;32:1366-1370. (Pubitemid 28522396)
6. Sharma SK, Kini A, Marmur JD et al. Cardioprotective effect of prior b-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: Benefit is extended to improvement in intermediate-term survival. Circulation 2000;102:166-172. (Pubitemid 30451772)
7. Uretsky B F, Birnbaum Y, Osman A, et al. Distal myocardial protection with in-tracoronary beta blocker when added to a GP IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheter Cardiovasc Interv 2008;72:488-497.
8. Enseleit F, Hurlimann D, Luscher T. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 2001;37(Suppl 1):S21.
9. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18(Suppl 2):S110-S115.
10. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-265. (Pubitemid 26266107)
11. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148. (Pubitemid 24176909)
12. Yusuf S, Pogue J, Myers M, et al. ACE inhibition in stable coronary artery disease. N Engl J Med 2005;352:937-939. (Pubitemid 40300307)
13. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: A systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006;47:1576-1583.
14. Bonnemeier H, Schäfer U, Ortak J, et al. Low doses of intracoronary enalaprilat suppress reperfusion-associated ventricular arrhythmias after primary percutaneous coronary interventions for acute myocardial infarction. Pacing Clin Electrophysiol 2007;30:S160-S165. (Pubitemid 46121833)
15. Schaefer U, Kurz T, Bonnemeier H, et al. Intracoronary enalaprilat during angio-plasty for acute myocardial infarction: Alleviation of postischaemic neurohumoral and inflammatory stress? J Intern Med 2007;261:188-200. (Pubitemid 46090327)
16. Leesar MA, Jneid H, Tang XL, et al. Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. J Am Coll Cardiol 2007;49:1607-1610. (Pubitemid 46551636)
17. Zhao JL, Yang YJ, Zhang YH, et al. Chronic pretreatment of ACE-I reduces no-reflow in patients with acute myocardial infarction treated with primary angio-plasty. Clin Cardiol 2007;30:130-134.
18. Shariff N, Dunbar C, Matsumura ME. Relation of pre-event use of inhibitors of the renin-angiotensin system with myocardial infarct size in patients presenting with a first ST-segment elevation myocardial infarction. Am J Cardiol 2010;106:646-649.
19. Aronow HD, Strawderman RL, Moscucci M, et al. Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention. Int J Cardiol 2010 Sep 22. [Epub ahead of print]
20. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
21. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178.
22. The Acute Infarction Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
23. Ertl G, Kloner RA, Alexander RW, et al. Limitation of experimental infarct size by angiotensin converting enzyme inhibition. Circulation 1982;65:40-48. (Pubitemid 12250888)
24. Hartman JC. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995;60:789-792.
25. Hock CE, Ribeiro GT, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985;109:222-228. (Pubitemid 16250856)
26. Ebrahimi R, Saleh J, Toggart E, et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: A meta-analysis. J Invasive Cardiol 2008;20:292-295. (Pubitemid 351940887)
27. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-1828. (Pubitemid 39330233)
28. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Car-diovasc Interv 2004;62:193-197. (Pubitemid 38788696)